NCT07131345 2025-08-20
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
National Cancer Center, China
Phase 1/2 Not yet recruiting
National Cancer Center, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences